BioCryst To Present at Two Upcoming Investor Conferences

BIRMINGHAM, Ala.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that executives from BioCryst are scheduled to present and provide corporate updates at the following investor conferences:

  • Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer of BioCryst, plans to present at JMP Securities 9th Annual Research Conference in San Francisco on Tuesday, May 11, 2010 at 12:00 p.m. Pacific Time.
  • Jon Stonehouse, President and Chief Executive Officer of BioCryst, plans to present at the Bank of America Merrill Lynch Healthcare Conference in New York on Wednesday, May 12, 2010 at 11:20a.m. Eastern Time.

Links to live audio Web casts and replays of both presentations may be accessed on the BioCryst Web site at www.biocryst.com.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds that are in late-stage pivotal trials; peramivir, a neuraminidase inhibitor for the treatment of influenza, and forodesine, an orally-available purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Additionally, BioCryst has a third product candidate, BCX4208—a next generation PNP inhibitor—in mid-stage trials for the treatment of gout. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company’s Web site at www.biocryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.

BCRXW



CONTACT:

BioCryst Pharmaceuticals
Robert Bennett, 919-859-7910

KEYWORDS:   United States  North America  Alabama

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Hospitals  Infectious Diseases  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.